• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环 miRNA 作为尿路上皮癌诊断生物标志物的独立验证。

Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma.

机构信息

Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Division of Pharmacotherapeutics, Keio University Faculty of Pharmacy, Tokyo, Japan.

出版信息

Cancer Sci. 2022 Oct;113(10):3510-3517. doi: 10.1111/cas.15496. Epub 2022 Aug 12.

DOI:10.1111/cas.15496
PMID:35848873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9530882/
Abstract

Urothelial carcinoma (UC) is an umbrella term for bladder cancers (BCa) and upper-tract urothelial carcinoma (UTUC), with BCa and UTUC sometimes detected concomitantly. The methods of detection for UC are often inaccurate or highly invasive, and, therefore, are thought to be unsatisfactory. Previously, we reported seven serum miRNAs as diagnostic markers for BCa. Here, we re-evaluated potential diagnostic miRNAs in different institutions. We prospectively analyzed serum samples obtained from 126 UC patients (BCa: 106 samples; UTUC: 14 samples; UTUC with BCa: six samples) and 50 noncancer controls by microarray analysis. We randomly assigned these samples into a training or a validation set. Biomarker candidate miRNAs were selected based on cross-validation scores in the training set of samples, with diagnostic power confirmed in the validation set. Among the diagnostic miRNAs identified in this way, miR-1343-5p and miR-6087 had been identified as potential diagnostic miRNAs in our previous study. In addition, we evaluated the association between the serum levels of identified miRNAs and the presence of UC risk conditions. The expression levels of several miRNAs correlate with the risk factors in participants without UC, which may be explained by the presence of a microscopic tumor or a precancerous lesion. In conclusion, we identified two robust miRNA diagnostic markers for UC detection. Further functional analysis is required to elucidate the mechanism by which alterations in the expression of these miRNAs occur.

摘要

尿路上皮癌 (UC) 是膀胱癌 (BCa) 和上尿路尿路上皮癌 (UTUC) 的统称,BCa 和 UTUC 有时同时被检测到。UC 的检测方法通常不准确或具有高度侵袭性,因此被认为不理想。此前,我们报道了七种血清 miRNA 作为 BCa 的诊断标志物。在这里,我们在不同机构重新评估了潜在的诊断 miRNA。我们通过微阵列分析前瞻性地分析了 126 例 UC 患者(BCa:106 例;UTUC:14 例;UTUC 伴 BCa:6 例)和 50 例非癌症对照者的血清样本。我们随机将这些样本分配到训练集或验证集中。基于训练集样本中的交叉验证分数选择候选 miRNA 标志物,并在验证集中确认诊断能力。通过这种方式鉴定的诊断 miRNA 中,miR-1343-5p 和 miR-6087 已在我们之前的研究中被鉴定为潜在的诊断 miRNA。此外,我们评估了鉴定的 miRNA 血清水平与 UC 风险状况之间的关联。在没有 UC 的参与者中,几种 miRNA 的表达水平与风险因素相关,这可能是由于存在微小肿瘤或癌前病变。总之,我们确定了两种用于 UC 检测的稳健 miRNA 诊断标志物。需要进一步的功能分析来阐明这些 miRNA 表达变化发生的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a0/9530882/fa02da5809e1/CAS-113-3510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a0/9530882/60569d3b7319/CAS-113-3510-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a0/9530882/fa02da5809e1/CAS-113-3510-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a0/9530882/60569d3b7319/CAS-113-3510-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/43a0/9530882/fa02da5809e1/CAS-113-3510-g001.jpg

相似文献

1
Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma.循环 miRNA 作为尿路上皮癌诊断生物标志物的独立验证。
Cancer Sci. 2022 Oct;113(10):3510-3517. doi: 10.1111/cas.15496. Epub 2022 Aug 12.
2
N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.血清免疫球蛋白 N-聚糖特征作为尿路上皮癌的诊断生物标志物。
Cancer Med. 2021 Feb;10(4):1297-1313. doi: 10.1002/cam4.3727. Epub 2021 Jan 16.
3
A Panel of Three Serum MicroRNAs as a Potential Diagnostic Biomarker for Urothelial Carcinoma.三血清 microRNA 标志物 panel 有望成为诊断尿路上皮癌的生物标志物。
Oncol Res Treat. 2022;45(6):344-352. doi: 10.1159/000523853. Epub 2022 Mar 1.
4
Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.一组 microRNA 基因的甲基化是膀胱癌检测的一种新型生物标志物。
Eur Urol. 2013 Jun;63(6):1091-100. doi: 10.1016/j.eururo.2012.11.030. Epub 2012 Nov 23.
5
Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer.利用全基因组鉴定尿细胞游离 microRNAs 进行膀胱癌的无创检测。
J Cell Mol Med. 2018 Mar;22(3):2033-2038. doi: 10.1111/jcmm.13487. Epub 2018 Jan 24.
6
Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer.血清 miR-125b-5p、miR-182-5p 和 miR-200c-3p 诊断试剂盒作为非侵入性生物标志物用于膀胱癌。
Clin Transl Oncol. 2022 May;24(5):909-918. doi: 10.1007/s12094-021-02741-3. Epub 2022 Jan 14.
7
Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder.miRNA-203 在膀胱癌液体活检中的无创诊断潜力。
Mol Cell Biochem. 2022 Sep;477(9):2173-2182. doi: 10.1007/s11010-022-04431-2. Epub 2022 Apr 20.
8
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma.上尿路尿路上皮癌中 miRNA 表达模式的预后价值。
BJU Int. 2014 May;113(5):813-21. doi: 10.1111/bju.12551.
9
Characterization of microRNAs expression profiling in one group of Chinese urothelial cell carcinoma identified by Solexa sequencing.通过 Solexa 测序鉴定的一组中国尿路上皮细胞癌中 microRNAs 表达谱的特征。
Urol Oncol. 2013 Feb;31(2):219-27. doi: 10.1016/j.urolonc.2010.11.007. Epub 2011 Jul 27.
10
Plasma miRNA profile is a biomarker associated with urothelial carcinoma in chronic hemodialysis patients.血浆微小RNA谱是一种与慢性血液透析患者尿路上皮癌相关的生物标志物。
Am J Physiol Renal Physiol. 2019 Jun 1;316(6):F1094-F1102. doi: 10.1152/ajprenal.00014.2019. Epub 2019 Mar 20.

引用本文的文献

1
Maximal and sub-maximal exercise tests alter PBMC microRNA expression: insights into sport- and sex-specific variations.最大负荷和次最大负荷运动测试会改变外周血单个核细胞的微小RNA表达:对运动和性别特异性差异的见解。
Front Physiol. 2025 Jul 17;16:1583870. doi: 10.3389/fphys.2025.1583870. eCollection 2025.
2
Diagnostic status and new explorations in upper urinary tract urothelial carcinoma: a literature review.上尿路尿路上皮癌的诊断现状与新探索:文献综述
Transl Androl Urol. 2024 Nov 30;13(11):2570-2586. doi: 10.21037/tau-24-326. Epub 2024 Nov 28.
3
Liquid biopsy in cancer current: status, challenges and future prospects.

本文引用的文献

1
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2020 年更新版。
Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24.
2
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.在上尿路尿路上皮癌中的辅助化疗(POUT 试验):一项 3 期、开放标签、随机对照试验。
Lancet. 2020 Apr 18;395(10232):1268-1277. doi: 10.1016/S0140-6736(20)30415-3. Epub 2020 Mar 5.
3
Emerging biomarkers for the diagnosis and monitoring of urothelial carcinoma.
癌症液体活检的现状、挑战与未来前景
Signal Transduct Target Ther. 2024 Dec 2;9(1):336. doi: 10.1038/s41392-024-02021-w.
用于尿路上皮癌诊断和监测的新兴生物标志物。
Res Rep Urol. 2018 Dec 14;10:251-261. doi: 10.2147/RRU.S173027. eCollection 2018.
4
Circulating miRNA panels for specific and early detection in bladder cancer.用于膀胱癌特异性和早期检测的循环 miRNA 面板。
Cancer Sci. 2019 Jan;110(1):408-419. doi: 10.1111/cas.13856. Epub 2018 Dec 12.
5
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018.膀胱癌的流行病学:2018 年系统回顾和当代危险因素更新。
Eur Urol. 2018 Dec;74(6):784-795. doi: 10.1016/j.eururo.2018.09.001. Epub 2018 Sep 26.
6
Diabetes mellitus and the risk of bladder cancer: A PRISMA-compliant meta-analysis of cohort studies.糖尿病与膀胱癌风险:一项符合PRISMA标准的队列研究的荟萃分析。
Medicine (Baltimore). 2017 Nov;96(46):e8588. doi: 10.1097/MD.0000000000008588.
7
Upper tract urothelial carcinoma: a different disease entity in terms of management.上尿路尿路上皮癌:在治疗方面是一种不同的疾病实体。
ESMO Open. 2017 Jan 24;1(6):e000126. doi: 10.1136/esmoopen-2016-000126. eCollection 2016.
8
Epidemiology of urothelial carcinoma.尿路上皮癌的流行病学
Int J Urol. 2017 Oct;24(10):730-734. doi: 10.1111/iju.13376. Epub 2017 May 21.
9
Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review.循环微小RNA和细胞外囊泡作为潜在的癌症生物标志物:一项系统综述。
Int J Clin Oncol. 2017 Jun;22(3):413-420. doi: 10.1007/s10147-017-1104-3. Epub 2017 Feb 27.
10
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.微小 RNA 治疗学:癌症和其他疾病治疗新时代的到来。
Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17.